Institutional & Family Asset Management, LLC Arvinas, Inc. Transaction History

Institutional & Family Asset Management, LLC

$846 Million
Q2 2024

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 08, 2023	BUY	$26.15 - $37.26 $26 - $37	1 Added 16.67%	7 $0
Q1 2022 May 11, 2022	SELL	$60.27 - $81.57 $60 - $81	-1 Reduced 14.29%	6 $0
Q3 2021 Nov 10, 2021	SELL	$73.2 - $107.87 $366 - $539	-5 Reduced 41.67%	7 $1,000
Q1 2021 May 06, 2021	BUY	$58.19 - $91.37 $698 - $1,096	12 New	12 $1,000

Others Institutions Holding ARVN

# of Institutions

224

Shares Held

70.9M

Call Options Held

1.52M

Put Options Held

346K

Vanguard Group Inc Valley Forge, PA

7.06M
Shares

$126 Million
0.0% of portfolio
Eco R1 Capital, LLC San Francisco, CA

6.73M
Shares

$120 Million
6.03% of portfolio
Black Rock Inc. New York, NY

6.26M
Shares

$111 Million
0.0% of portfolio
Price T Rowe Associates Inc Baltimore, MD

4.1M
Shares

$72.9 Million
0.01% of portfolio
Rtw Investments, LP New York, NY

3.33M
Shares

$59.3 Million
1.04% of portfolio

View Full List

About ARVINAS, INC.

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $945M
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

More about ARVN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Institutional & Family Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Institutional & Family Asset Management, LLC with notifications on news.

Account